Intensity of warfarin coagulation in the antiphospholipid syndrome

被引：8
作者：
Crowther M.A. [1 ]
机构：
[1] Division of Hematology and Thromboembolism, McMaster University, St Joseph's Hospital, 50 Charlton Ave, East Hamilton, ON
来源：
Current Rheumatology Reports | 2010年 / 12卷 / 1期
关键词：
Anticoagulation; Antiphospholipid syndrome; Lupus anticoagulant; Warfarin;
D O I：
10.1007/s11926-009-0070-9
中图分类号：
学科分类号：
摘要：
Antiphospholipid syndrome is a condition with an increased propensity for both arterial and venous thrombosis. Compared with the normal population there is also a higher rate of recurrence. Most evidence exists for the use of warfarin in the secondary prevention of thromboembolism, aiming for an international normalized ratio between 2.0 and 3.0. Care must be taken with all anticoagulants because of the increased risk of bleeding. Several other strategies are available if warfarin fails, including the addition of aspirin, increasing the warfarin target range, and use of heparin. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：64 / 69
页数：5
相关论文
共 27 条
  • [11] Hereng T., Lambert M., Hachulla E., Et al., Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients, Lupus, 17, pp. 11-15, (2008)
  • [12] Erkan D., Merrill J.T., Yazici Y., Sammaritano L., Buyon J.P., Lockshin M.D., High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin, Arthritis and Rheumatism, 44, 6, pp. 1466-1467, (2001)
  • [13] Clark C.A., Spitzer K.A., Crowther M.A., Et al., Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss, J Rheumatol, 34, pp. 992-996, (2007)
  • [14] Lim W., Crowther M.A., Eikelboom J.W., Management of antiphospholipid antibody syndrome: A systematic review, Journal of the American Medical Association, 295, 9, pp. 1050-1057, (2006)
  • [15] Schulman S., Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, American Journal of Medicine, 104, 4, pp. 332-338, (1998)
  • [16] Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, SUPPL. 6, (2008)
  • [17] Kearon C., Ginsberg J.S., Anderson D.R., Kovacs M.J., Wells P., Julian J.A., MacKinnon B., Demers C., Douketis J., Turpie A.G., Van Nguyen P., Green D., Kassis J., Kahn S.R., Solymoss S., Desjardins L., Geerts W., Johnston M., Weitz J.I., Hirsh J., Gent M., Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor, Journal of Thrombosis and Haemostasis, 2, 5, pp. 743-749, (2004)
  • [18] Levine S.R., Brey R.L., Tilley B.C., Et al., Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke, JAMA, 291, pp. 576-584, (2004)
  • [19] Khamashta M.A., Cuadrado M.J., Mujic F., Et al., The management of thrombosis in the antiphospholipid-antibody syndrome, N Engl J Med, 332, pp. 993-997, (1995)
  • [20] Kunz R., Oxman A.D., The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials, BMJ, 317, pp. 1185-1190, (1998)
123